ClinicalTrials.gg
CompletedNCT04542252Updated Apr 27, 2021

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

A Phase 1 interventional study of SyB V-1901 and Cyclosporine in Drug Drug Interaction, sponsored by SymBio Pharmaceuticals. Completed at 1 site in Japan. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-27.

Sponsored by SymBio Pharmaceuticals · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Study summary

To evaluate the effect of coadministered cyclosporine on the pharmacokinetics of brincidofovir following simultaneous administration of SyB V-1901 with cyclosporine, or coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion in healthy adult subjects

Read the detailed description

This study is an open-label, randomized and crossover study designed to evaluate the effect of cyclosporine on the pharmacokinetics of SyB V-1901. Healthy adult subjects will receive an IV dose of SyB V-1901 alone, simultaneous administration of SyB V-1901 with cyclosporine, and coadministration of cyclosporine at 2 hours after completion of SyB V-1901 infusion. Eligible subjects will be randomized to one of two groups, to receive the treatment sequence of assigned group.

02

Conditions studied

  • Drug Drug Interaction
03

In context

Lead sponsor

SymBio Pharmaceuticals is the lead sponsor of 25 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Healthy adult male aged between 20 to 55 years at
  • from 18 to 32 kg/m2 with a body weight of ≥ 50 kg
  • ≥ 60 mL/min at screening
  • Judged to be in good general health, based on the review of medical history and the screening and Pre-Day1 examination

Main Exclusion Criteria:

  • Positive for antibody, or HBs antigen, or antibody at the screening or within 6 months prior to the start of screening
  • Have a history of infection of SARS-CoV-2, or subjects who have close contact with infected patients of SARS-CoV-2 within 2 weeks prior to screening or visit to epidemic area of SARS-CoV-2 infection in outside of Japan or have close contact with person who visit to epidemic area of SARS-CoV-2 infection within 2 weeks prior to screening
  • Positive for SARS-CoV-2 polymerase chain reaction (PCR) in lower respiratory tract specimens, nasopharyngeal swabs or saliva and so on at screening or have a fever ≥ 37.5 °C and respiratory symptoms
  • Have a history of drug abuse or alcohol dependence within 2 years prior to the start of screening
  • Have a history of gastrointestinal disorders or cholecystectomy etc., which could interfere with the absorption of cyclosporine or could interfere with normal gastrointestinal anatomy or motility, but except for uncomplicated appendectomy.
  • Have a history or symptoms of cardiovascular disease, including but not limited to coronary artery disease, hypertension, congestive heart disease, and cardiac disorder.
  • Have a history of hematological disorders or have a risk of gastrointestinal bleeding
  • Have a history of chronic liver disease or hepatic impairment, including but not limited to alcoholic liver disease, chronic viral hepatitis, hepatitis, steatosis or hemochromatosis.
  • Have increased (ALT) or Aspartate aminotransferase (AST) greater than at screening or Pre-Day1
  • History of Gilbert's syndrome or increased total greater than 1.5x the upper limit of the normal range at screening or Pre-Day1
  • Have symptoms of infection within 2 weeks prior to Pre-Day1
  • Have clinically significant abnormal at the screening or Pre-Day1, or a clinically significant iron deficiency
  • Have a history of blood donation or had clinically significant blood loss within 30 days prior to Day 1, or /plasma donation within 7 days prior to Day 1
  • Have received any drug, or device within 30 days prior to Day1
  • History of tobacco- or nicotine-containing product use within 6 months prior to Day1
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Group 1

    SyB V-1901 alone, Simultaneous administration of SyB V-1901 and cyclosporine, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion

    Drug: SyB V-1901 · Drug: Cyclosporine

  • Experimental
    Group 2

    Simultaneous administration of SyB V-1901 and cyclosporine, SyB V-1901 alone, Coadministration of cyclosporine at 2 hours after the completion of SyB V-1901 infusion

    Drug: SyB V-1901 · Drug: Cyclosporine

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of brincidofovir (BCV)

    Time frame: From initiation of SyB V-1901 administration though 16 days

  2. Area under the plasma concentration versus time curve (AUC) of BCV

    Time frame: From initiation of SyB V-1901 administration though 16 days

Secondary outcomes

  1. Cmax of cidofovir (CDV)

    Time frame: From initiation of SyB V-1901 administration though 16 days

  2. AUC of CDV

    Time frame: From initiation of SyB V-1901 administration though 16 days

  3. Cmax of Intercellular Cidofovir diphosphate (CDV-PP) in Peripheral Blood Mononuclear Cells (PBMCs)

    Time frame: From initiation of SyB V-1901 administration though 18 days

  4. AUC of Intercellular CDV-PP in PBMCs

    Time frame: From initiation of SyB V-1901 administration though 18 days

  5. Cmax of cyclosporine in blood

    Time frame: From initiation of cyclosporine administration though 16 days

  6. AUC of cyclosporine in blood

    Time frame: From initiation of cyclosporine administration though 16 days

  7. Number of subjects with adverse events (AE)

    Time frame: Follow up 22 days post dose

  8. Number of subjects with severity of AEs

    Time frame: Follow up 22 days post dose

  9. Number of subjects with abnormal findings for laboratory parameters

    Time frame: Follow up 22 days post dose

  10. Number of subjects with abnormal findings for blood pressure

    Time frame: Follow up 22 days post dose

  11. Number of subjects with abnormal findings for respiratory rate

    Time frame: Follow up 22 days post dose

  12. Number of subjects with abnormal findings for heart rate

    Time frame: Follow up 22 days post dose

  13. Number of subjects with abnormal findings for temperature

    Time frame: Follow up 22 days post dose

Other outcomes

  1. Genotype of CYP4F2

    Time frame: Pre-Day1

  2. Genotype of OATP1B1

    Time frame: Pre-Day1

07

Study locations

1 site
  • Research Site
    Hachioji-shi, Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Dec 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2020
First posted
Sep 9, 2020
StartActual
Nov 9, 2020
Primary completionActual
Dec 22, 2020
CompletionActual
Jan 29, 2021
Last update
Apr 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04542252
Responsible party
Sponsor
First posted
Sep 9, 2020
Start date
Nov 9, 2020
Primary completion
Dec 22, 2020
Completion
Jan 29, 2021
Last update
Apr 27, 2021

Study contacts

Takeshi Yoshida
study director · SymBio Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brincidofovir · Cyclosporine

Start the discussion